Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Apollomics Inc.
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
August 14, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
August 13, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
August 08, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
July 16, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
July 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Presentation at the 2024 BIO International Convention
May 29, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Private Placement Financing and Addition to Board of Directors
May 08, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 25, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 10, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 28, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 26, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
January 19, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
January 17, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
GLYC
Apollomics to Present at the 2024 Biotech Showcase
January 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 04, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
November 29, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 31, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 26, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
October 23, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
October 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Tickers
APLM
APLMW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.